Nick Stone appointed Head of Investor Relations at Fresenius | FSE
The internationally experienced healthcare and capital market expert Nick Stone has been appointed Head of Investor Relations at Fresenius, effective October 1.
Fresenius
Holding Companies & Conglomerates · Germany · 175,771 Employees
View Company Info for Free
About
Headquarters
1 Else-kröner-str., Bad Homburg vor der Hoehe, ...Phone Number
+49 4961726080Website
www.fresenius.comRevenue
$25.2 BillionStock Symbol
FREMost Recent Scoops
Sep 13 2024
Hiring Plans
Sep 9 2024
Open Position
Who is Fresenius
Fresenius SE & Co. KGaA is a Germany-based holding company, operating in the healthcare sector, with products and services for dialysis, hospitals and outpatient medical care and management. The company is headquartered in Bad Homburg , Germany.Read more
Fresenius Org Chart
Is Fresenius your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Fresenius launches new products
Congratulate Masked Content for being promoted to Masked Content at Fresenius
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Fresenius has recently received funding, and reach out quickly before it becomes old news!
Check out if Fresenius is spiking on competitors!
Fresenius, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Fresenius has new funding data
Click to see if Fresenius had a recent Job posting/layoffs
Earning: See what the market has to say on Fresenius recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Fresenius as Masked Content
Find 2 more new buyers
Similar Companies to Fresenius
Analyze insights from companies similar to Fresenius and make strategic comparisons based on performance, financial data, growth and unique benchmarks.
- Fresenius Medical Care North A...70,000
$14.1B - Baxter International60,000$15B
- DaVita70,000$12.3B
- Tenet Healthcare78,810$20.9B
- McKesson45,000$313.8B
- Medline Industries39,000$23.2B
- Bristol-Myers Squibb34,100$45.5B
- Henry Schein26,000$12.5B
More similar companies
Fresenius Email Formats
Fresenius uses at least 5 email formats with first.last (ex. John.Smith@fresenius.com) being used 42% of the time
| Fresenius Email Formats | Percentage | |
|---|---|---|
| first.last | John.Smith@fresenius.com | 42% |
| first.last | John.Smith@fresenius-netcare.com | 21.6% |
| first_last | John_Smith@fresenius.com | 10.1% |
| first.last | John.Smith@freseniusmedicalcare.com | 5% |
| first.last | John.Smith@fmc-ag.com | 4.5% |
Get Verified Emails
View Email Formats for Fresenius
Fresenius Employee Growth Rate
View Fresenius’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Fresenius Tech Stack
A closer look at the technologies used by Fresenius
Most Recent Scoops
Sep 13 2024
Hiring Plans
Sep 9 2024
Open Position
Sep 9 2024
Open Position
Sep 8 2024
Open Position
Sep 6 2024
Open Position
Fresenius News & Media
Fresenius SE & Co. KGaA (FSNUF) Q2 2024 Earnings Call Transcript
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2024 Earnings Conference Call July 31, 2024 7:30 AM ETCompany ParticipantsMarkus Georgi - Head of Investor...Fresenius beats Q2 view on strong unit performance, cost savings
(Reuters) -German healthcare group Fresenius beat second-quarter operating profit expectations on Wednesday, citing strong performance at its Kabi and Helios units, and progress in group-wide cost savings. It reported earnings before interests and taxes (EBIT) of 660 million euros ($714 million), up 16% from a year ago. Analysts were expecting an EBIT of 636 million euros, according to a consensus of forecasts from Vara Research.Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States
LAKE ZURICH, Ill.--(BUSINESS WIRE)-- #FreseniusKabi--Fresenius, via its operating company Fresenius Kabi, announced today the immediate availability in the U.S. of its biosimilar Tyenne® (tocilizumab-aazg), in a subcutaneous formulation, which will increase access to affordable and cost-effective treatment options for use in the treatment of chronic autoimmune diseases. Tyenne is indicated for use in the treatment of chronic autoimmune diseases for certain indications of the reference product, AFresenius SE & Co. KGaA (ETR:FRE) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Fresenius SE KGaA's (ETR:FRE) stock is up by a considerable 19% over the past three months. But the company's key...
Read more news
Top Companies in Germany
Top 10 companies in Germany by revenue
Top 10 companies in Germany by number of employees
Top 10 companies in Germany by total funding amount
Frequently Asked Questions Regarding Fresenius
Fresenius SE & Co. KGaA is a Germany-based holding company, operating in the healthcare sector, with products and services for dialysis, hospitals and outpatient medical care and management. The company is headquartered in Bad Homburg , Germany.... Read More
